{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T19:31:33Z","timestamp":1793043093586,"version":"4.5.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T00:00:00Z","timestamp":1748304000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ther Innov Regul Sci"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>The ICH E9(R1) estimand framework provides a systematic approach to ensure alignment among clinical trial objectives, trial conduct, statistical analyses, and interpretation of results, however, whether it can be readily utilized for the pharmacoepidemiologic safety studies has not been established. We selected articles on drug safety published in the Journal Pharmacoepidemiology and Drug Safety (PDS), during 2020 to investigate whether estimand attributes were well defined in the study design and reporting. We found that among twenty-five articles selected, nineteen were cohort studies and six were nested case-control studies. All studies had well-defined exposure, outcome, target population, and population level summary. The term intercurrent event (ICE) was not mentioned in any of the studies; however, many cohort studies discussed drug discontinuation, treatment modification and terminal events, and strategies to handle them. All studies used methods to control for confounding: propensity score methods or covariate adjustment, or both for cohort studies; matching and covariate adjustment for the nested case-control studies. We conclude that while the estimand framework can serve to add clarity and precision to pharmacoepidemiologic safety studies, more detailed considerations are required for bias assessment to compensate for the lack of randomization and other shortcomings in observational studies. Recent pharmacoepidemiology frameworks, such as Target Trial Emulation, STaRT-RWE, HARPER could be combined with the complementary principals from the estimand framework to help achieve the study objectives.<\/jats:p>","DOI":"10.1007\/s43441-025-00780-4","type":"journal-article","created":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T11:24:14Z","timestamp":1748345054000},"page":"971-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Review of Recent Pharmacoepidemiologic Post-Market Safety Studies Through the Lens of the Estimand Framework"],"prefix":"10.1007","volume":"59","author":[{"given":"Yong","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Haddad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Snyder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,27]]},"reference":[{"issue":"1","key":"780_CR1","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s41687-020-00218-5","volume":"4","author":"R Lawrance","year":"2020","unstructured":"Lawrance R, Degtyarev E, Griffiths P, et al. What is an estimand & how does it relate to quantifying the effect of treatment on patient-reported quality of life outcomes in clinical trials? J Patient Rep Outcomes. 2020;4(1):68.","journal-title":"J Patient Rep Outcomes"},{"key":"780_CR2","unstructured":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (2019). ICH E9 Addendum on Estimands (PDF). https:\/\/database.ich.org\/sites\/default\/files\/E9-R1_Step4_Guideline_2019_1203.pdf"},{"issue":"5","key":"780_CR3","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1002\/pst.2196","volume":"21","author":"H Li","year":"2022","unstructured":"Li H, Wang C, Chen WC, et al. Estimands in observational studies: some considerations beyond ICH E9 (R1). Pharm Stat. 2022;21(5):835\u201344.","journal-title":"Pharm Stat"},{"key":"780_CR4","unstructured":"Food and Drug Administration (FDA). Best Practices for Conducting and Reporting Pharmacoepidemiologic Safety Studies Using Electronic Healthcare Data Sets. May 2013. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/best-practices-conducting-and-reporting-pharmacoepidemiologic-safety-studies-using-electronic"},{"key":"780_CR5","unstructured":"European Medicines Agency (EMA). Heads of medicines agency guideline on good pharmacovigilance practices (GVP) module VIII \u2013 post-authorization safety studies (PASS) template. September 2012 https:\/\/www.ema.europa.eu\/en\/documents\/other\/guidance-format-content-protocol-non-interventional-post-authorisation-safety-studies_en.pdf"},{"key":"780_CR6","unstructured":"ISPE\u2019s guidelines for good pharmacoepidemiology practice (GPP) section on protocol development. 2015 https:\/\/www.pharmacoepi.org\/resources\/policies\/guidelines-08027\/#1"},{"key":"780_CR7","doi-asserted-by":"publisher","unstructured":"Wang SV, Pinheiro S, Hua W et al. STaRT-RWE: structured template for planning and reporting on the implementation of real world evidence studies. BMJ. 2021;372:m4856. Published 2021 Jan 12. https:\/\/doi.org\/10.1136\/bmj.m4856","DOI":"10.1136\/bmj.m4856"},{"issue":"1","key":"780_CR8","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/pds.5507","volume":"32","author":"SV Wang","year":"2023","unstructured":"Wang SV, Potteg\u00e5rd A, Crown W, et al. HARmonized protocol template to enhance reproducibility of hypothesis evaluating real-world evidence studies on treatment effects: a good practices report of a joint ISPE\/ISPOR task force. Pharmacoepidemiol Drug Saf. 2023;32(1):44\u201355.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"780_CR9","unstructured":"ENCePP Guide on Methodological Standards in Pharmacoepidemiology. Revision 10. July 2023 https:\/\/www.encepp.eu\/standards_and_guidances\/methodologicalGuide.shtml"},{"issue":"8","key":"780_CR10","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","volume":"183","author":"MA Hernan","year":"2016","unstructured":"Hernan MA, Robins JM. Using big data to emulate a target trial when a randomized trial is not available. Am J Epidemiol. 2016;183(8):758\u201364.","journal-title":"Am J Epidemiol"},{"issue":"1","key":"780_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1002\/pds.4909","volume":"29","author":"J Busby","year":"2020","unstructured":"Busby J, Karasneh R, Murchie P, et al. The role of 5\u03b1-reductase inhibitors in gastro-oesophageal cancer risk: A nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29(1):48\u201356.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"780_CR12","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1002\/pds.4954","volume":"29","author":"LC Saiz","year":"2020","unstructured":"Saiz LC, Gil M, Alonso A, et al. Use of methylphenidate and risk for valvular heart disease: A case-control study nested in the BIFAP cohort. Pharmacoepidemiol Drug Saf. 2020;29(3):288\u201395.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"780_CR13","doi-asserted-by":"publisher","first-page":"558","DOI":"10.1002\/pds.4976","volume":"29","author":"Y Miyamoto","year":"2020","unstructured":"Miyamoto Y, Iwagami M, Aso S, et al. Pregabalin and injury: A nested case-control and case-crossover study. Pharmacoepidemiol Drug Saf. 2020;29(5):558\u201364.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"780_CR14","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1002\/pds.4993","volume":"29","author":"A Saad","year":"2020","unstructured":"Saad A, Goldstein J, Margalit O, et al. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29(5):599\u2013604.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"780_CR15","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1002\/pds.5034","volume":"29","author":"JH Lai","year":"2020","unstructured":"Lai JH, Wang MT, Wu CC, et al. Risk of severe hypoglycemic events from amiodarone-sulfonylureas interactions: A population-based nested case-control study. Pharmacoepidemiol Drug Saf. 2020;29(8):842\u201353.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR16","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/pds.5106","volume":"29","author":"SM Shin","year":"2020","unstructured":"Shin SM, Jeong HE, Lee H, et al. Association between Domperidone use and adverse cardiovascular events: A nested case-control and case-time-control study. Pharmacoepidemiol Drug Saf. 2020;29(12):1636\u201349.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"2","key":"780_CR17","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1002\/pds.4920","volume":"29","author":"W Umek","year":"2020","unstructured":"Umek W, Gleiss A, Bodner-Adler B, et al. The role of prescription drugs in female overactive bladder syndrome-A population-wide cohort study. Pharmacoepidemiol Drug Saf. 2020;29(2):189\u201398.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"3","key":"780_CR18","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/pds.4930","volume":"29","author":"G Br\u00f6ms","year":"2020","unstructured":"Br\u00f6ms G, Kieler H, Ekbom A, et al. Anti-TNF treatment during pregnancy and birth outcomes: A population-based study from Denmark, Finland, and Sweden. Pharmacoepidemiol Drug Saf. 2020;29(3):316\u201327.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"780_CR19","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1002\/pds.4986","volume":"29","author":"U Gungabissoon","year":"2020","unstructured":"Gungabissoon U, Kirichek O, El Baou C, et al. Comparison of long-term use of prolonged-release ropinirole and immediate-release dopamine agonists in an observational study in patients with Parkinson\u2019s disease. Pharmacoepidemiol Drug Saf. 2020;29(5):591\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"780_CR20","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1002\/pds.5014","volume":"29","author":"J Salas","year":"2020","unstructured":"Salas J, Morley JE, Scherrer JF, et al. Risk of incident dementia following Metformin initiation compared with noninitiation or delay of antidiabetic medication therapy. Pharmacoepidemiol Drug Saf. 2020;29(6):623\u201334.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"780_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1002\/pds.5024","volume":"29","author":"Y Xu","year":"2020","unstructured":"Xu Y, Wang T, Yang Z, et al. Sulphonylureas monotherapy and risk of hospitalization for heart failure in patients with type 2 diabetes mellitus: A population-based cohort study in China. Pharmacoepidemiol Drug Saf. 2020;29(6):635\u201343.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"780_CR22","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1002\/pds.5007","volume":"29","author":"TY Chyou","year":"2020","unstructured":"Chyou TY, Nishtala R, Nishtala PS. Comparative risk of parkinsonism associated with olanzapine, Risperidone and quetiapine in older adults-a propensity score matched cohort study. Pharmacoepidemiol Drug Saf. 2020;29(6):692\u2013700.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"780_CR23","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/pds.5017","volume":"29","author":"TN Thai","year":"2020","unstructured":"Thai TN, Sarayani A, Wang X, et al. Risk of pregnancy loss in patients exposed to mycophenolate compared to azathioprine: A retrospective cohort study. Pharmacoepidemiol Drug Saf. 2020;29(6):716\u201324.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"780_CR24","doi-asserted-by":"publisher","first-page":"736","DOI":"10.1002\/pds.5009","volume":"29","author":"E Skovlund","year":"2020","unstructured":"Skovlund E, Selmer R, Skurtveit S, et al. In utero exposure to analgesic opioids and Language development in 5-year old children. Pharmacoepidemiol Drug Saf. 2020;29(6):736\u201344.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"8","key":"780_CR25","doi-asserted-by":"publisher","first-page":"832","DOI":"10.1002\/pds.5069","volume":"29","author":"M Webster-Clark","year":"2020","unstructured":"Webster-Clark M, St\u00fcrmer T, Edwards JK, et al. Real-world on-treatment and initial treatment absolute risk differences for Dabigatran vs warfarin in older US adults. Pharmacoepidemiol Drug Saf. 2020;29(8):832\u201341.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"780_CR26","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1002\/pds.5036","volume":"29","author":"BN Harding","year":"2020","unstructured":"Harding BN, Wiggins KL, Jensen PN, et al. Opioid, gabapentinoid, and nonsteroidal anti-inflammatory medication use and the risks of atrial fibrillation and supraventricular ectopy in the Multi-Ethnic study of atherosclerosis. Pharmacoepidemiol Drug Saf. 2020;29(9):1175\u201382.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"10","key":"780_CR27","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1002\/pds.5065","volume":"29","author":"TA Althunian","year":"2020","unstructured":"Althunian TA, de Boer A, Groenwold RHH, et al. Rivaroxaban was found to be noninferior to warfarin in routine clinical care: A retrospective noninferiority cohort replication study. Pharmacoepidemiol Drug Saf. 2020;29(10):1263\u201372.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR28","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1002\/pds.5130","volume":"29","author":"L Fanning","year":"2020","unstructured":"Fanning L, Wong ICK, Li X, et al. Gastrointestinal bleeding risk with Rivaroxaban vs aspirin in atrial fibrillation: A multinational study. Pharmacoepidemiol Drug Saf. 2020;29(12):1550\u201361.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR29","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.1002\/pds.5132","volume":"29","author":"C Srinivas","year":"2020","unstructured":"Srinivas C, Odsbu I, Linder M. Risk of common infections among individuals with psoriasis in Sweden: A nationwide cohort study comparing Secukinumab to ustekinumab. Pharmacoepidemiol Drug Saf. 2020;29(12):1562\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR30","doi-asserted-by":"publisher","first-page":"1596","DOI":"10.1002\/pds.5088","volume":"29","author":"M Mahic","year":"2020","unstructured":"Mahic M, Hernandez-Diaz S, Wood M, et al. In utero opioid exposure and risk of infections in childhood: A multinational nordic cohort study. Pharmacoepidemiol Drug Saf. 2020;29(12):1596\u2013604.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR31","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1002\/pds.5090","volume":"29","author":"DJ Selig","year":"2020","unstructured":"Selig DJ, Brown AJ, DeLuca JP, et al. Risk of type 2 diabetes mellitus by antimuscarinic agents among adult females receiving care in the military health system. Pharmacoepidemiol Drug Saf. 2020;29(12):1605\u201315.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR32","doi-asserted-by":"publisher","first-page":"1616","DOI":"10.1002\/pds.5103","volume":"29","author":"A Gilsenan","year":"2020","unstructured":"Gilsenan A, Midkiff K, Harris D, et al. Assessing the incidence of osteosarcoma among teriparatide users based on medicare part D and US state cancer registry data. Pharmacoepidemiol Drug Saf. 2020;29(12):1616\u201326.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR33","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1002\/pds.5098","volume":"29","author":"D Barthold","year":"2020","unstructured":"Barthold D, Marcum ZA, Gray SL, et al. Alzheimer\u2019s disease and related dementias risk: comparing users of non-selective and M3-selective bladder antimuscarinic drugs. Pharmacoepidemiol Drug Saf. 2020;29(12):1650\u20138.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR34","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1002\/pds.5159","volume":"29","author":"L Pasina","year":"2020","unstructured":"Pasina L, Lucca U, Tettamanti M. Relation between anticholinergic burden and cognitive impairment: results from the Monzino 80-plus population-based study. Pharmacoepidemiol Drug Saf. 2020;29(12):1696\u2013702.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"780_CR35","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1002\/pds.5164","volume":"29","author":"D Sato","year":"2020","unstructured":"Sato D, Uda K, Kumazawa R, et al. Mortality and morbidity following postoperative use of short-term, low-dose quetiapine vs Risperidone in patients with diabetes: analysis using a National inpatient database. Pharmacoepidemiol Drug Saf. 2020;29(12):1703\u20139.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"780_CR36","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","volume":"79","author":"MA Hern\u00e1n","year":"2016","unstructured":"Hern\u00e1n MA, Sauer BC, Hern\u00e1ndez-D\u00edaz S, et al. Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses. J Clin Epidemiol. 2016;79:70\u20135.","journal-title":"J Clin Epidemiol"},{"key":"780_CR37","doi-asserted-by":"publisher","first-page":"k182","DOI":"10.1136\/bmj.k182","volume":"360","author":"MA Hern\u00e1n","year":"2018","unstructured":"Hern\u00e1n MA. How to estimate the effect of treatment duration on survival outcomes using observational data. BMJ. 2018;360:k182.","journal-title":"BMJ"},{"issue":"5","key":"780_CR38","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1097\/01.ede.0000135174.63482.43","volume":"15","author":"MA Hern\u00e1n","year":"2004","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S, Robins JM. A structural approach to selection bias. Epidemiology. 2004;15(5):615\u201325.","journal-title":"Epidemiology"},{"issue":"1","key":"780_CR39","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","volume":"9","author":"MA Hern\u00e1n","year":"2012","unstructured":"Hern\u00e1n MA, Hern\u00e1ndez-D\u00edaz S. Beyond the intention-to-treat in comparative effectiveness research. Clin Trials. 2012;9(1):48\u201355.","journal-title":"Clin Trials"},{"issue":"2","key":"780_CR40","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1080\/19466315.2023.2259829","volume":"16","author":"J Chen","year":"2023","unstructured":"Chen J, Scharfstein D, Wang H, et al. Estimands in Real-World evidence studies. Stat Biopharm Res. 2023;16(2):257\u201369.","journal-title":"Stat Biopharm Res"},{"key":"780_CR41","doi-asserted-by":"publisher","unstructured":"Hampson LV, Chu J, Zia A et al. (2023) Combining the target trial and estimand frameworks to define the causal estimand: an application using Real-World data to contextualize a Single-Arm trial, statistics in biopharmaceutical research, https:\/\/doi.org\/10.1080\/19466315.2023.2190931","DOI":"10.1080\/19466315.2023.2190931"},{"key":"780_CR42","unstructured":"Polito L, Liang Q, Pal N et al. August. Applying the estimand and target trial frameworks to external control analyses using observational data: a case study in the solid tumor setting. 2022 https:\/\/arxiv.org\/ftp\/arxiv\/papers\/2208\/2208.06707.pdf"}],"updated-by":[{"DOI":"10.1007\/s43441-025-00821-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T00:00:00Z","timestamp":1749859200000}}],"container-title":["Therapeutic Innovation &amp; Regulatory Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00780-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s43441-025-00780-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s43441-025-00780-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,18]],"date-time":"2025-09-18T20:54:18Z","timestamp":1758228858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s43441-025-00780-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,27]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["780"],"URL":"https:\/\/doi.org\/10.1007\/s43441-025-00780-4","relation":{},"ISSN":["2168-4790","2168-4804"],"issn-type":[{"value":"2168-4790","type":"print"},{"value":"2168-4804","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,27]]},"assertion":[{"value":"26 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s43441-025-00821-y","URL":"https:\/\/doi.org\/10.1007\/s43441-025-00821-y","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}]}}